Compositions and methods of treating retinal disease

Patent metadata

Field	Value
Publication number	US-9364471-B2
Application number	US-201414581453-A
Country	US
Kind code	B2
Filing date	Dec 23, 2014
Priority date	May 26, 2005
Publication date	Jun 14, 2016
Grant date	Jun 14, 2016

Abstract

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

First claim

What is claimed:

1. A method of treating macular degeneration and other forms of retinal disease mediated by accumulation of A2E and/or lipofuscin in a subject, the method comprising administering to the subject in need thereof a composition comprising a compound of formula IIIa:

or a pharmaceutically acceptable salt thereof, wherein:
A is;

B is a halogen atom, hydroxyl, carbamoyl, aryl or amino;
p is 0, 1, 2, or 3;
D is unbranched lower alkyl;
L is a single bond or CH 2 ; and
X, Y, and Z are each, independently, N, NH, O, S, CB, CH, or absent, such that at least one of X, Y, and Z is N or NH; wherein X, Y, and Z and the carbon atoms to which they are attached form a 5- or 6-membered optionally substituted heterocyclic ring.

2. The method of claim 1 , wherein
one of X or Z is N and the remaining X or Z is O;
Y is absent; such that X and Z and the carbon atoms to which they are attached form a 5-membered heterocyclic ring; and
p is 1.

3. The method of claim 2 , wherein L is a single bond.

4. The method of claim 3 , wherein X is O and Z is N.

5. The method of claim 3 , wherein X is N and Z is O.

6. The method of claim 4 , wherein B is aryl.

7. The method of claim 5 , wherein B is aryl.

8. The method of claim 6 , wherein B is phenyl.

9. The method of claim 7 , wherein B is phenyl.

10. The method of claim 3 , wherein D is CH 3 .

11. The method of claim 10 , wherein the compound is

or pharmaceutically acceptable salts thereof.

12. The method of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Aldeyra Therapeutics Inc

Inventors

• Jordan Thomas A
• Dowling John E
• Chabala John Clifford

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P27/00

  Drugs for disorders of the senses · CPC title

• A61K31/4418

  having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine · CPC title

• C07D215/38 Primary

  Nitrogen atoms (nitro radicals C07D215/18) · CPC title